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Chelonid fibropapillomatosis-associated herpesvirus (CFPHV) is an alphaherpesvirus believed to cause
marine turtle fibropapillomatosis (FP). A serodiagnostic assay was developed for monitoring sea turtle
populations for CFPHV exposure. CFPHV glycoprotein H (gH) expressed in recombinant baculovirus was used
in an enzyme-linked immunosorbent assay (ELISA) to detect virus-specific 7S turtle antibodies. Using captive-
reared green turtles (Chelonia mydas) with no history of virus exposure as “known negatives” and others with
experimentally induced FP as “known positives,” the assay had 100% specificity but low sensitivity, as
seroconversion was detected in only half of the turtles bearing experimentally induced tumors. Antibodies were
detected only in samples collected after cutaneous fibropapillomas appeared, consistent with observations that
tumors are significant sites of virion production and antigen expression and the possibility that prolonged/
repeated virus shedding may be required for adequate stimulation of 7S antibody responses to gH. Natural
routes of infection, however, may produce higher seroconversion rates. High gH antibody seroprevalences
(80%) were found among wild green turtles in three Florida localities with different FP prevalences, including
one site with no history of FP. In addition, all eight loggerhead turtles (Caretta caretta) tested were seropositive
despite FP being uncommon in this species. The possibility that CFPHV infection may be common relative to
disease suggests roles for environmental and host factors as modulators of disease expression. Alternatively,
the possibility of other antigenically similar herpesviruses present in wild populations cannot be excluded,
although antibody cross-reactivity with the lung/eye/trachea disease-associated herpesvirus was ruled out in
this study.
Marine turtles with fibropapillomatosis (FP) are infected
with a novel alphaherpesvirus known as chelonid fibropapillo-
matosis-associated herpesvirus (CFPHV) (17). Detection of
viral genomic DNA, primarily within fibropapillomas of all
turtles with spontaneous FP, virus shedding from tumor epi-
dermal keratinocytes, and cotransmission of virus with disease
in experimentally induced FP makes CFPHV infection the
major risk factor and strongly implicates it as the etiologic
agent of this disease (17, 20, 32, 33, 36, 37). In recent decades,
the prevalence of FP has increased dramatically, and the dis-
ease has spread to new localities around the world (16, 45). A
phylogenetic study of CFPHV variants found in tumors
showed, however, that this group of viruses has been present in
turtle populations far longer than the FP panzootic (17). Thus,
the current panzootic is not due to a newly emergent patho-
genic virus variant. This raises questions about the relative
importance of ecological factors affecting the rate of virus
transmission within and between populations compared to fac-
tors affecting disease expression (the development, progres-
sion, and regression of tumors) in influencing the prevalence
and spread of epizootic FP (10, 17).
Epidemiologic studies designed to answer these questions
and to evaluate populations for susceptibility to FP outbreaks
require methods to detect the major risk factor, CFPHV ex-
posure, independently of clinically apparent disease. To date,
the spread of CFPHV infections in sea turtle populations has
been documented through surveillance for turtles with clini-
cally apparent tumors and detection of virus DNA within these
tissues. To address the need to detect viral exposure indepen-
dently of disease, a primary goal of our research program has
been to produce sensitive and specific diagnostic assays to
detect antibodies to this virus.
CFPHV has not been propagated successfully in culture as a
source of viral antigens. An immunohistochemical assay using
formalin-fixed tumor tissue sections as targets demonstrated
that turtles with either experimental or spontaneous FP had
antibodies to antigens present in epidermal foci of productive
virus replication (18). The utility of this assay has been limited,
however, by the availability of tissue containing these foci.
Furthermore, the antigens in such foci are uncharacterized and
likely to vary among tissue preparations. Further complicating
matters, antibody cross-reactivity with lung/eye/trachea disease-
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associated herpesvirus (LETHV), another alphaherpesvirus
that is associated with pneumonia, conjunctivitis, and tracheitis
in green turtles (28), has been demonstrated with this assay (5,
7). Specifically, turtles that had been immunized with inacti-
vated LETHV culture lysates showed antibody reactivity to
CFPHV inclusions in FP tissue sections (5). Some wild green
turtles with FP also had antibody reactivity to LETHV-infected
cells and culture lysates (7). One cross-reacting antigen, UL26
protease, has been identified (6).
In vitro expression of recombinant viral proteins provides a
source of target antigens that can be evaluated separately for
their utility in diagnostic assay development. Since large por-
tions of the unique long (UL) region of the CFPHV genome
have been cloned and sequenced, open reading frames for a
number of viral proteins are available for expression and eval-
uation (13, 17). Glycoproteins were selected for recombinant
expression because their location on the surface of viral par-
ticles made them likely candidates for humoral immune re-
sponses (35, 44). In addition, glycoproteins may be relatively
virus specific. For example, glycoprotein G has been found to
distinguish antibody reactivity to the closely related human
herpesviruses 1 and 2 (HSV-1 and HSV-2) (15, 34).
This paper reports baculovirus expression of recombinant
CFPHV glycoprotein H with and without glycoprotein L co-
expression and the development and application of an enzyme-
linked immunosorbent assay (ELISA) to detect turtle antibod-
ies to recombinant CFPHV glycoprotein H. This assay was
used to evaluate plasma immune responses of turtles that were
experimentally infected with CFPHV and to describe the se-
roprevalence of CFPHV glycoprotein H antibodies in free-
ranging turtles from three sites with very different FP disease
prevalences.
MATERIALS AND METHODS
CFPHV glycoprotein peptides. The open reading frame sequences for CFPHV
gH (UL22) and gL (UL1) were retrieved from the partially sequenced UL region
of the CFPHV Florida variant A genome (GenBank accession number
AY644454) (17). Candidate immunogenic peptides were designed and synthe-
sized, and purity was confirmed by mass spectrometry (SigmaGenosys, The
Woodlands, TX). Rabbits were immunized with keyhole limpet hemocyanin-
conjugated peptides to produce peptide-specific antisera for detecting protein
expression. Unconjugated peptides were also used as antigens to screen plasma
samples from turtles with spontaneous FP for immunoreactivity to identify sam-
ples that could serve as positive controls in the recombinant glycoprotein H
protein ELISA.
Expression of recombinant gH (UL22) and gL (UL1). Full-length open read-
ing frames for viral glycoproteins were PCR amplified from a reference DNA
sample containing CFPHV Florida variant A (17) using primers in the flanking
sequences upstream and downstream of each open reading frame. UL22 was
amplified using primers 5-AACCTGTTGAGCGACTTCCA-3 and 5-TCTAG
CCCCTTTTTCCACCT-3, and UL1 was amplified using primers 5-TCCGAC
AACCGTCTTCGA-3and 5-CACCTCGCTGCTCTTAGTTA-3. Each prod-
uct was cloned into a plasmid vector (Invitrogen, Carlsbad, CA), and clones were
fully sequenced to confirm the absence of PCR-induced mutations. Viral open
reading frames were fused in frame to myc and six-histidine epitopes in the
plasmid vector pcDNA4myc-His (Invitrogen), such that the epitope tags were
located at the carboxyl termini of the fusion proteins. The myc-His tag was
positioned at the carboxyl terminus of gL, while the tag was fused slightly
upstream of the hydrophobic membrane-spanning domain near the carboxyl
terminus of gH. The myc-His-tagged gL and gH were then inserted into a
baculovirus transfer vector. The vector used was pCPE20. This is a derivative of
the baculovirus transfer vector pUL1393 into which the amino terminus of
human carboxypeptidase E (CPE) (42) has been cloned. The CPE segment
provided a proven signal peptide for effective expression of type I membrane
proteins in the baculovirus system followed by a furin cleavage site. Immediately
downstream of the furin cleavage site was a unique XbaI cloning site and further
downstream was a unique XhoI site. The myc-His-tagged gL and gH were PCR
amplified from immediately downstream of the predicted N-terminal signal pep-
tides through the stop codon immediately following the epitope tags. XbaI sites
were included in the 5 PCR primers and XhoI sites in the 3 PCR primers. The
epitope-tagged gL and gH were fused in frame downstream of the CPE signal
sequence. Thus, the final plasmid contained from N to C termini, the CPE signal
peptide, the CPE furin cleavage site, the viral protein, Myc epitope, six-His tag,
and the stop codon. Sequences of all plasmids were confirmed again to rule out
PCR-induced errors. The CPE-fusion vectors were then used to generate infec-
tious baculoviruses, which were then cloned, and the proteins were expressed in
baculovirus-infected SF9 cells (Kinnakeet Biotechnology, Richmond, VA). Pel-
lets from approximately 1 liter of infected cells were solubilized in 20 mM
HEPES pH 7.4 plus protease inhibitors (Sigma Chemical Co., St. Louis, MO),
sonicated, and then centrifuged at 15,000 rpm for 30 min in a Sorvall SS-34 rotor.
The pellet (membrane-enriched fraction) was resuspended in 1% Nonidet P-40
(NP-40) in phosphate-buffered saline on ice and centrifuged under the same
conditions, yielding NP-40-soluble (supernatant) and insoluble (pellet) fractions.
Proteins were enriched from the various fractions using the six-His tag by Ni
chelate-Sepharose chromatography. Total culture lysates and the proteins from
various fractions were tested by Western blotting using anti-six-His antibodies
(Kinnakeet Biotechnology).
ELISA detection of antibodies to recombinant gH. The antigen used in the
ELISA was protein enriched from NP-40-soluble fractions of the initial lysate
pellet of gH-expressing cells. A series of ELISAs were conducted to optimize the
antigen-coating concentration and concentrations of reagents. The following
ELISA conditions were used in this study. Recombinant glycoprotein H (affinity-
enriched NP-40-soluble fraction) was immobilized at a concentration of 2 g
ml1 in Tris-buffered saline (TBS), pH 7.4, in Maxisorp plates (NUNC, Kam-
strup, Denmark). Half of the wells on each ELISA plate were coated with
antigen, and the remaining half were coated with 1% bovine serum albumin
(BSA) in TBS as controls for nonspecific binding. Following overnight incuba-
tion at 4°C, the plates were blocked with 1% BSA in TBS. After washing with
TBS containing 0.1% Tween 20 (TBST), sea turtle plasma was tested in duplicate
on both antigen-coated and BSA-coated wells at a dilution of 1:5 in TBST
adjusted to 0.5 M NaCl containing 1% BSA (hi-salt TBST-BSA). Each assay
plate included blank (no plasma) wells and wells containing negative and positive
assay control plasma samples. Following incubation for 1 h and washing (three
cycles) with TBST, biotinylated mouse monoclonal antibody HL858, specific for
green turtle 7S immunoglobulin heavy chain (23), was added at a concentration
of 1 g ml1 in hi-salt TBST-BSA. Detection used streptavidin-conjugated
alkaline phosphatase (Sigma) diluted 1:1,000 in hi-salt TBST-BSA followed by
100 l per well of substrate (p-nitrophenyl phosphate disodium [Zymed Labo-
ratories, San Francisco, CA] in diethanolamine buffer, pH 9.8). The average of
three optical density readings taken at 405 nm (OD405) per plate was used for
subsequent calculations.
Antigen-specific optical densities were calculated as the difference between the
average OD405 measured in recombinant glycoprotein H-coated wells and that
measured in BSA-coated wells for each sample. The antigen-specific immuno-
reactivity of each sample was scored relative to negative pool and positive assay
control samples as follows: ELISA score  (sample OD – negative control
OD)/(positive control OD).
The negative assay control included on each plate was pooled plasma from a
set of 10 “known negative” captive-reared green turtles (below). The positive
assay control was plasma from a wild green turtle with FP that had strong
immunoreactivity to the glycoprotein H-derived synthetic peptide (CKALKSG
KIEGEDRK). This turtle was selected from a group of 10 green turtles with FP
that were tested for immunoreactivity to a set of CFPHV glycoprotein-derived
synthetic peptides. The peptide ELISA was run as described above, except that
each unconjugated peptide at 100 ng ml1 in TBS served as antigen.
Sample ELISA scores of 3 standard deviations above the mean antigen-
specific ELISA scores of a set of 10 “known negative” samples (below) were
interpreted as positive. Selected plasma samples that tested positive at a 1:5
dilution were tested at serial dilutions ranging from 1:5 to 1:500. Titers were
defined as the highest dilution at which the sample OD remained greater than
10% above the negative pool OD. Western blot assays were performed on
selected ELISA-positive samples to confirm antigen-specific immunoreactivity.
Plasma samples from FP transmission experiments. A series of green turtles
that had been raised from eggs in captivity for use in transmission experiments
provided a source of plasma samples with well-controlled exposure to CFPHV
and limited exposure to other pathogens (21, 24). Samples that were collected
from these turtles prior to any experimental exposure to CFPHV (preinoculation
samples and controls) were used as our population of “known negatives.” Pooled
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plasma from 10 of these animals was used as the negative pool sample in all
ELISA plates (above). Plasma samples from 20 additional “known negative”
turtles were tested independently to evaluate assay specificity.
Captive-reared green turtles that were experimentally exposed to CFPHV
were used to characterize the 7S antibody response (4, 23) to recombinant
CFPHV glycoprotein H. These transmission experiments are described in ref-
erence 21. Briefly, four turtles were assigned to one of four groups, and each
group was inoculated by intradermal injection and skin scarification with FP
tumor homogenate from a single donor, a free-ranging green turtle with spon-
taneous disease. An additional turtle was assigned to each group as an uninocu-
lated contact control. Blood samples were collected from all animals prior to
inoculation and at several time points (at 3- to 6-month intervals) over the
following 20 months. Turtles were checked weekly for tumor development.
Tumors developed at sites of inoculation in all the treated turtles from three of
the groups. Uninoculated contact controls and all turtles from the fourth group,
inoculated with tumor homogenate from donor 4, failed to develop FP (21).
Since infection could only be verified by PCR in turtles that developed tumors,
only those experimentally exposed turtles that developed FP were classified as
“known positives.”
In another transmission experiment, two captive-reared turtles were immu-
nized by repeated injections with inactivated LETHV until they had developed
strong anti-LETHV antibody responses (up to 1:3,200) as detected by ELISA (5,
7). Both immunized turtles and an unimmunized control were subsequently
challenged with FP tumor homogenates containing CFPHV. Plasma samples
collected prior to LETHV immunization and at various time points throughout
the experiment were tested by ELISA at a 1:5 dilution.
Retrospectively, all donor tumor homogenates used in these transmission
studies were tested by PCR using consensus primers (17, 41), CFPHV-specific
primers (10), and LETHV-specific primers to confirm the presence of CFPHV
and check for the presence of herpesviruses other than CFPHV.
Plasma samples from free-ranging turtle populations. Archived plasma sam-
ples were tested from free-ranging green turtles (Chelonia mydas) and logger-
heads (Caretta caretta) that were netted at three study sites on the Atlantic coast
of Florida in 1999. Turtle populations at these sites have been monitored for FP
since 1982, 1988, and 1993, respectively, by one of the authors (L. M. Ehrhart).
These sites represent three distinct near-shore feeding habitats for juvenile green
turtles, have markedly different disease prevalences, defined as the percentage of
captured animals with detectable cutaneous tumors, and are in close geographic
proximity. The Indian River Lagoon site (Indian River County, FL; 2749N,
8026W) is located about 3 km south of Sebastian Inlet and consists of shallow
water (1 to 3 m) and a muddy bottom with drift algae and seagrass beds. The
prevalence of FP among green turtles at this site has averaged 50% (ranging
from 28 to 72%) since monitoring began in 1982 (26). The Wabasso Beach Reef
site is approximately 1 km due east of the Indian River Lagoon site in open water
east of the barrier island and is a Sabellariid worm reef located in about 2 to 3 m
of water. The prevalence of FP at this site since monitoring began in 1988 until
1997 was 0%. Since 1997, however, the FP prevalence has ranged from 8 to 21%
(26). The Trident Submarine Basin is a human-made embayment located near
the mouth of the ship channel of Port Canaveral, Brevard County, FL, approx-
imately 60 km north of the other two sites. The basin is approximately 600 m wide
by 1,200 m long with a water depth of 13 m and a marginal shelf up to 3 m in
depth. Prevalence of FP at this locality has been 0% since monitoring began in
1993.
Blood samples (3 to 10 ml) were collected in heparinized syringes from the
dorsal cervical sinus. Plasma was separated by centrifugation and frozen in
aliquots at 20°C and then stored at 70°C.
RESULTS
Baculovirus vectors were engineered to express full-length
CFPHV gH and gL with six-His tags at their carboxyl termini.
Western blot analysis of lysates from gH-encoding baculovirus-
infected cells revealed expression proteins with apparent mo-
lecular masses of approximately 75 and 105 kDa that were
detected with anti-six-His monoclonal antibodies (not shown).
Rabbit antiserum generated against gH-specific peptide con-
firmed the identity of these proteins, which may represent
differentially processed forms of gH (Fig. 1). Identically sized
proteins were identified in cultures coexpressing gH with gL. In
both cultures, gH proteins were recovered predominantly from
the detergent (NP-40)-soluble and insoluble fractions, al-
though some (105-kDa) gH protein was also found in the lysate
supernatant from cells coinfected with gH and gL. Immunore-
active proteins of 20 and 24 kDa were detected in the gH-
plus-gL culture lysate by Western blotting with CFPHV gL
peptide-specific rabbit antiserum (Fig. 1), as well as anti six-His
antibodies (not shown), confirming gL expression.
Glycoprotein H for use as the ELISA antigen was enriched
from the NP-40-soluble fraction of culture lysate infected with
recombinant baculovirus expressing gH alone using a nickel-
Sepharose affinity chromatography column (Fig. 2A). Both 75-
and 105-kDa immunoreactive proteins were recovered from
this fraction (Fig. 2B).
ELISA development. Preliminary ELISA screening of 10
plasma samples from wild turtles with spontaneous FP against
a set of synthetic peptides derived from CFPHV glycoproteins
found two samples that reacted strongly with the glycoprotein
H-derived synthetic peptide (CKALKSGKIEGEDRK). The
sample with the highest immunoreactivity was included as the
positive assay control in every ELISA plate. The ELISA score
for this sample averaged 0.90 and had a coefficient of variation
of 6% in 25 independent assays. Plasma samples from 10 un-
infected captive reared green turtles were used to establish
expected optical density values and ELISA scores for negative
samples. Pooled plasma from these 10 uninfected turtles was
used as the negative assay control, with an ELISA score de-
fined as 0. When individual samples were tested relative to this
negative pool assay control, they had ELISA scores ranging
from 	0 to 0.06. An ELISA score of 0.12, equivalent to 3
standard deviations above 0, was established as the cutoff value
for a negative score.
Serology of turtles used in FP transmission experiments.
Plasma collected from 20 additional uninfected captive-reared
turtles, sampled prior to experimental inoculation with tumor
homogenates containing CFPHV, served as the “known neg-
ative” population to evaluate assay specificity. The ELISA
FIG. 1. Expression of CFPHV glycoprotein H alone or in combi-
nation with glycoprotein L in recombinant baculovirus-infected insect
cells. Lane 1, culture lysate expressing glycoprotein H alone; lane 2,
culture lysate coexpressing glycoprotein H and glycoprotein L; lane 3,
control baculovirus lysate; MW, molecular size markers. Proteins with
apparent molecular masses of 75 and 105 kDa were detected with
rabbit antisera to glycoprotein H peptide (CKALKSGKIEGEDRK) at
a dilution of 1:50,000. Proteins with apparent molecular masses of 20
and 24 kDa were detected with rabbit antisera to glycoprotein L
peptide (CGKPESILTEGLKSE) at a 1:50,000 dilution.
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scores of these samples all fell below the cutoff value and
within the same range (	0 to 0.06) as those used in the neg-
ative pool control. Consequently, this ELISA had a specificity
of 100%. Furthermore, additional samples collected from un-
infected contact controls at various time points throughout the
course of transmission experiments also fell below an ELISA
score of 0.06.
Specific antibody responses to CFPHV glycoprotein H were
detected only among green turtles that developed detectable
fibropapillomas after they were experimentally infected via
intradermal inoculation with tumor homogenates. Four turtles
that never developed FP following inoculation with tumor ho-
mogenate from a single donor were excluded from the popu-
lation of “known positives” because CFPHV infection could
not be confirmed. They did not have detectable 7S antibody
responses to gH in any of the samples tested (ELISA scores of
	0.06).
Ten turtles that did develop experimentally induced tumors
were defined as the “known positive” population. Figure 3A
presents the ELISA scores of samples from these turtles rela-
tive to time since the start of the transmission experiment.
Figure 3B presents the same ELISA data relative to the time
when tumors were first detected (time zero). Plasma samples
collected 2 to 4 months after inoculation but prior to develop-
ment of visible fibropapillomas had ELISA scores of 	0.06
(Fig. 3A). Several of these ELISA-negative samples were col-
lected on the days that individual cases of FP were first de-
tected (Fig. 3B). The earliest samples that were interpreted as
ELISA positive (ELISA scores of 0.12) were collected from
9 to 11 months after experimental infection (Fig. 3A). This
corresponded to seroconversion being detected initially in
samples collected between 4 and 11 months after tumors were
first observed (Fig. 3B).
Ultimately, half of the “known positive” turtles had at least
one plasma sample that was interpreted as ELISA positive
during the course of experiment, while the other half did not.
Thus, the sensitivity of this ELISA was 50% across all time
samples. The 7S antibody response appeared to be sustained
for several months in three turtles, with positive scores found
in two or more consecutive plasma samples over a 3- to
6-month period. In two other turtles the response was more
transient, with only a single time point testing positive (Fig. 3A
and B). Thus, on any particular sampling date in this experi-
ment, no more than three turtles with tumors tested positive,
yielding a sensitivity estimate of 30% for a single time point
population sample. Seropositive samples had anti-gH titers
ranging from 1:50 to 1:100.
Lack of cross-reactivity of plasma from LETHV-immunized
turtles. Additional experimental turtles were studied to ad-
dress concerns about potential assay cross-reactivity with a
distantly related turtle herpesvirus, LETHV (6, 7). Plasma
samples from two turtles that had been serially immunized with
inactivated LETHV and subsequently challenged via inocula-
tion with FP tumor homogenates were tested for antibodies to
CFPHV recombinant glycoprotein H. All samples collected
prior to CFPHV inoculation were seronegative (titers 	 1:5),
including samples collected 2 and 3 months post-LETHV im-
munization that had robust anti-LETHV antibody titers (up to
1:3,200) detected in an ELISA using LETHV-infected culture
lysate (5, 7). Thus, despite developing robust antibody re-
sponses against LETHV, in neither turtle were these antibod-
ies cross-reactive with CFPHV glycoprotein H. A third unim-
munized (control) turtle was ELISA negative to both LETHV
and CFPHV glycoprotein H at these time points.
All three turtles were subsequently challenged by intrader-
mal injection with FP homogenates containing CFPHV and
within 6 months developed FP at the inoculation sites. Thus,
the antibody response against inactivated LETHV that oc-
curred in two turtles was unable to protect against FP tumor-
igenesis (5). Plasma samples collected approximately 17
months after tumor development (23 months after CFPHV
infection) were available for testing. One previously LETHV-
immunized turtle tested positive for anti-CFPHV glycoprotein
H antibodies and had a titer of 1:500. This turtle eventually
also developed tumors at anatomic sites other than those in-
oculated. The samples from the other previously LETHV-
immunized and the unimmunized control turtles were seroneg-
ative for CFPHV. Thus, seroprevalence was 33% among these
known CFPHV-exposed turtles in plasma sampled at approx-
imately 2 years postinfection.
Donor FP tissues used to experimentally infect turtles and
transmit FP were tested retrospectively by PCR using consen-
sus primers and LETHV-specific primer sets and found to be
FIG. 2. Enrichment of recombinant glycoprotein H from NP-40
detergent-soluble culture lysate using Ni-Sepharose. (A) Coomassie
blue-stained proteins from total culture lysate expressing glycoprotein
H alone (lane 1) and Ni-Sepharose-bound proteins eluted with imid-
azole (lane 2). (B) Immunoblot of eluted Ni-Sepharose-bound pro-
teins using rabbit antisera to glycoprotein H peptide (CKALKSGKIE
GEDRK) at a dilution of 1:100,000.
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LETHV negative. The only products that were amplified using
consensus primers were CFPHV sequences.
Serology of wild turtles. Plasma was collected from 171 free-
ranging green turtles at three study sites on the east central
Atlantic coast of Florida. These sites historically differed in
their FP prevalences. The population samples collected for
analysis had FP tumor prevalences in the ranges reported for
these sites in long-term monitoring studies (26), with Indian
River Lagoon having the highest FP prevalence (61.8%), fol-
lowed by Wabasso Beach Reef (18.2%), and then Trident
Submarine Basin (0%). Table 1 presents the FP disease preva-
FIG. 3. Plasma 7S antibody reactivity to Ni-Sepharose affinity-enriched recombinant CFPHV glycoprotein H among 10 “known positive” green
turtles over time. “Known positives” were experimentally infected turtles that developed FP at inoculation sites. CFPHV infection was confirmed
by PCR of tumor DNA. (A) ELISA scores plotted against time relative to the start of the experiment. (B) ELISA scores plotted against time
relative to the first detection of FP in each animal (time zero). Time points sampled prior to time zero were from turtles that did not have tumors,
while those sampled after time zero were from turtles with detectable tumors. Reference ELISA scores (means 
 standard deviations) for 10
“known negative” controls (f) and the positive assay control sample () are included for comparison. The cutoff value (0.12) corresponds to 3
standard deviations above the mean score of “known negative” pool sample.
TABLE 1. Seroprevalence versus FP tumor prevalence among free-
ranging green turtles at three Florida localities
Locality
(no. of turtles)
FP tumor
prevalence
(%)
Anti-CFPHV gH
seroprevalence (%)
All
turtles
Turtles with
no apparent
FP
Turtles
with
FP
Indian River Lagoon
(55)
61.8 87.3 85.7 88.2
Wabasso Beach
Reef (55)
18.2 80 75.6 100
Trident Basin (61) 0 83.6 83.6 NAa
a NA, not applicable (no turtles with apparent FP).
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lences and the 7S anti-glycoprotein H seroprevalences for tur-
tles from these three localities. ELISA scores for wild green
turtle samples at the three sites ranged from 0 to 2.12. There
were no statistically significant differences in ELISA scores
either between these three localities or between turtles with
tumors and those without, based on Kruskal-Wallis tests (46).
High-scoring samples from each locality had anti-glycoprotein
H titers of up to 1:500. Immunoblot assays confirmed the
antigen-binding specificity of selected plasma samples with
positive ELISA scores (Fig. 4). Seroprevalence (percentage of
turtles with ELISA scores of 0.12) ranged from 80% to
87.3% among the three localities. There was no association
between seroprevalence and locality (chi-square P  0.59) and
no correlation between seroprevalence and FP prevalence
across sites. Positive ELISA scores were not associated with
current disease status in either of the two sites with FP (Indian
River Lagoon and Wabasso Beach Reef; chi-square P  0.79
and P  0.08, respectively). That is, no more individuals with
FP had positive serology than those without disease.
The sample population of green turtles from the Trident
Basin had an anti-CFPHV glycoprotein H seroprevalence of
83.6% despite there being no history of FP in that population
for over 15 years of monitoring (26). Changing the ELISA
score cutoff value had no effect on these overall relationships.
Several of the field samples used in this study (n  29) had
been tested previously by ELISA against LETHV (8). This
sample population included 4 LETHV negatives that tested
CFPHV negative, 20 LETHV negatives that tested CFPHV
positive, 4 that were double positive, and 1 that was LETHV
positive but CFPHV negative. Thus, there was no association
between 7S immunoreactivity to LETHV and CFPHV in this
sample (chi-square P  0.86).
Plasma samples from eight juvenile loggerhead turtles
(Caretta caretta) from Indian River Lagoon were also tested by
ELISA. ELISA scores ranged from 0.21 to 2.13 (average of
1.02 
 0.78). Thus, all were seropositive despite having a low
FP prevalence in this sample (12.5%) and in long-term moni-
toring of this study site (L. Ehrhart, unpublished).
DISCUSSION
Specificity of gH as an assay target. Selection of gH was
guided by concern about assay cross-reactivity between CFPHV
and LETHV (6, 7). Among the glycoproteins for which pub-
lished nucleotide sequences were available for comparison
(UL22 and UL27), gH (UL22) was chosen for antigen devel-
opment because it had lower sequence identity (30%) with its
cognate sequence from LETHV (GenBank accession number
EU194838). In contrast, gB (UL27) had about 40% amino acid
sequence identity with the LETHV gB (GenBank accession
number AY124577). Glycoprotein B is relatively conserved
among herpesviruses, and cross-reactions have been reported
among the gB homologues of several human herpesviruses as
well as among other mammalian herpesviruses (2, 9, 30, 31).
Baculovirus-expressed glycoprotein H provided a well-char-
acterized and readily produced antigen for assay development.
Studies with other herpesviruses have shown that gL helps
transport gH to the cell surface (43). While coexpression of gL
with gH might facilitate gH antigen recovery, there was con-
cern that the presence of gL in the ELISA would increase
cross-reactivity. Fortunately, the overall amount of gH antigen
recovered by expression of gH alone was similar to that with gL
coexpression.
High specificity and limited sensitivity for 7S antibody re-
sponses of captive-reared green turtles. Captive-reared green
turtles used in FP transmission experiments provided a popu-
lation with known exposure history to herpesviruses (known
negatives and known positives) essential for ELISA develop-
ment. They also provided initial insights on the development of
virus-specific antibody responses under relatively controlled
conditions that are useful in interpreting serologic results from
wild turtle populations (unknowns). The ELISA developed in
this study was highly specific (100%), as only infected turtles
developed seroreactivity. Consequently, the predictive value of
a positive test result is high, and positive results should reliably
indicate exposure to CFPHV. On the other hand, assay sensi-
tivity was low, as seroconversion was detected only in some
turtles that developed FP, even though PCR confirmed that all
were infected. As a consequence of low sensitivity, the predic-
tive value of negative assay results is low (19), and negative
serology cannot rule out infection.
A number of factors may explain why some turtles with FP
did not seroconvert while others evidenced only transient se-
roconversion in this experiment. Glycoprotein H is expressed
late (gamma phase) during productive virus infection, which to
date has been observed sporadically and focally only in the
epidermis of cutaneous tumors (20, 25). During early stages of
tumor development virus may be in an eclipse phase with
limited exposure of structural antigens such as gH to the host
immune system. Also, it is well known in some herpesvirus-
induced neoplasias for infection to remain latent with only a
fraction of viral genes being expressed in proliferating trans-
formed cells while virion production involving expression of
the full set of viral structural proteins occurs in other tissues (1,
FIG. 4. Immunoblot demonstrating the anti-gH antibody-binding
specificity of ELISA-positive turtle plasma. The antigen used was re-
combinant baculovirus-infected insect cell culture lysate coexpressing
glycoprotein H and glycoprotein L (lanes 1 to 3) and control baculo-
virus culture lysate (lane 4). Plasma samples were diluted 1:20 in
blocking buffer. Lane 1, blocking buffer-only control; lane 2, ELISA
negative control; lanes 3 and 4, ELISA-positive field sample. Turtle 7S
antibodies were detected with monoclonal antibody HL858 (1 g
ml1) followed by peroxidase-conjugated goat anti-mouse IgG (diluted
1:5,000) in blocking buffer. The ELISA-positive sample specifically
reacted with proteins consistent with gH (75 kDa) and gL (20
kDa).
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29). FP appears to be a proliferative disorder of dermal fibro-
blasts with variable involvement of tumor epidermis, and there
is no evidence that these tumor fibroblasts themselves produce
viral particles (20, 25). Thus, even in clinically apparent FP,
some tumors may not produce viral particles, or express
enough gH to stimulate seroconversion. Furthermore, plasma
7S immunoglobulin Y (IgY) immune responses, like those of
mammalian IgG, result from heavy chain class switching fol-
lowing repeated antigenic stimulation (4, 23). Thus, the prob-
ability of eliciting detectable 7S IgY immunoreactivity to gH
may vary as a function of how much virus is produced and shed
over time and possibly whether there is subcutaneous exposure
and/or systemic spread (viremia). All tumors that occurred in
this study were surgically resected approximately 11 months
after the experiment was begun, and recurrent tumors were
periodically resected thereafter, thus reducing antigen expo-
sure from primary skin tumors. Nevertheless, plasma samples
collected from these turtles when tumors were first removed all
(100%) showed immunoreactivity to viral antigens present in
epidermal foci of virus production in tumor sections by an
immunohistochemical assay (18). Thus, experimentally in-
fected turtles produce antibodies targeted to additional viral
antigens than just gH. These other viral antigens could lead to
more sensitive assays; however, they must be evaluated to
understand their effects on specificity.
High prevalences of anti-CFPHV gH antibodies among wild
turtles. Wild green turtle populations at three localities in
Florida all had high seroprevalences of antibody reactivity to
CFPHV gH despite large differences in FP prevalences. The
lack of association between antibody immunoreactivity to gH
and current clinical disease in the two localities with ongoing
FP outbreaks, Indian River Lagoon and Wabasso Beach Reef,
can be explained as follows. Based on the experimental find-
ings that seroconversion occurred late relative to disease onset,
if at all, some free-ranging individuals with FP were expected
to test negative. Furthermore, the apparently unaffected (tu-
mor-free) portion of the population may include turtles that
had FP but have fully recovered. Hirama (26) documented that
in the Indian River Lagoon population approximately 87% of
turtles with FP that were recaptured at intervals greater than
10 months showed evidence of tumor regression. Assuming
that turtles that are recovering from FP seroconvert, it is pos-
sible that a high percentage of apparently unaffected turtles in
the sites with ongoing FP outbreaks may have anti-CFPHV
antibodies. It was surprising, however, that seroprevalences
were similar despite a nearly threefold difference in FP prev-
alence between these two sites, especially since the outbreak at
the Wabasso Beach Reef site was more recent and had been
going on for only about 2 years at the time samples were
collected.
The fact that turtles from the Trident Basin also had a high
seroprevalence (80%) despite no history of FP in the popula-
tion (0% prevalence) since monitoring began in 1993 (26)
cannot be readily explained by a model that requires tumor
development for seroconversion. Given the long monitoring
history at this site, it is highly improbable that this is a popu-
lation that has fully recovered from a past FP outbreak. Ex-
trapolating from transmission studies, the ELISA was not ex-
pected to detect antibodies to gH in individuals that had not
developed FP (subclinical infection). It is conceivable, how-
ever, that the intradermal inoculations used in experimental
infections may not fully reflect the routes of transmission in
nature and that robust antibody responses to natural infection
might develop independently of the appearance of cutaneous
tumors. This hypothesis postulates that nontumor tissues,
which have yet to be identified, support CFPHV replication
and gH expression in cryptically infected turtles. To date, how-
ever, CFPHV has only reliably been detected in turtles with FP
(20, 27).
The possibility that virus infection and seroconversion may
occur in the absence of clinically apparent FP suggests that
CFPHV infection alone is not sufficient for disease expression.
Although studies showing a tight association of CFPHV with
tumors are consistent with the hypothesis that this virus is
involved in FP tumorigenesis (10, 13, 17, 32, 36), a variety of
biological and physical factors may modulate whether or not
CFPHV infection leads to FP disease (22). In this regard,
CFPHV infection may be understood in light of other prolif-
erative skin diseases caused by alphaherpesviruses and may
even serve as a model for these diseases. In humans, for ex-
ample, HSV, which typically causes focal vesicular and ulcer-
ative skin lesions, may cause hyperplastic lesions in the context
of chronic host immunodeficiency (3). Many factors may mod-
ulate host immune function. One possibility is that another
virus may interact with CFPHV in FP pathogenesis, perhaps by
causing host immunodeficiency (20). Such interactions are rec-
ognized in human herpesvirus-associated proliferative diseases
such as Kaposi’s sarcoma, involving human immunodeficiency
virus and human herpesvirus-8, and cutaneous verrucaeform
lesions, involving human immunodeficiency virus and human
herpesvirus-3 (11, 12, 14, 39).
Cross-reactivity with related chelonid herpesviruses. An-
other possible explanation for the high prevalence of CFPHV
gH-seropositive turtles in the wild Florida populations is that
the ELISA also detected antibodies produced in response to
infection with antigenically similar nontumorigenic herpesvi-
ruses. Cross-reactivity with LETHV was a particular concern in
this study because this had been demonstrated in other assays
and because there was serologic evidence of exposure to
LETHV in the Florida population (7, 8). However, there was
no association between immunoreactivity to recombinant
CFPHV glycoprotein H and immunoreactivity to LETHV cul-
ture lysate among wild turtles. Furthermore, the reported se-
roprevalence of LETHV antibodies in the Florida population
of approximately 21.6% across the same three sites during the
same time period (8) is too low to account for the 80%
seroprevalence to CFPHV in this study. In addition, both cap-
tive-reared turtles that were immunized with inactivated
LETHV developed high anti-LETHV titers but remained se-
ronegative to CFPHV glycoprotein H.
The presence of cross-reacting antibodies to other chelonid
herpesviruses that may infect the wild population cannot be
ruled out until antigens from these viruses become available
for study. Possible candidates include two herpesviruses re-
cently reported in Florida loggerheads (40). Although one of
these appears to be highly similar to LETHV, the other is
novel. Another candidate is chelonid herpesvirus-1, Greypatch
disease herpesvirus, which has been observed in posthatchling
green turtles raised in mariculture in the Caribbean (38). Nev-
ertheless, serological assays that use well-characterized recom-
VOL. 15, 2008 ELISA FOR TURTLE ANTIBODIES TO CHELONID HERPESVIRUS gH 849
binant antigens, such as those described here, will be the best
way to differentiate among antibody responses to antigenically
similar viruses.
Implications for FP epizootiology. The ELISA to detect
antibody exposure to CFPHV glycoprotein H described in this
report allowed an important hypothesis about the relationship
between viral infection and FP disease in free-ranging sea
turtle populations to be tested for the first time (10, 17). The
finding that CFPHV infection (as measured by antibody expo-
sure to gH) is highly prevalent along the east coast of Florida,
even in a population historically free of FP, suggests that FP
outbreaks in this region are less limited by environmental fac-
tors affecting virus transmission than they are by environmen-
tal or host factors affecting disease expression and whether or
not turtles develop FP. It will be important to survey turtle
populations in other regions to determine if similar seropreva-
lences exist elsewhere and to begin to correlate CFPHV infec-
tion with other environmental and host cofactors that may play
a role in FP outbreaks around the world. In addition, the
spatial distribution and association of specific closely related
CFPHV variants found in turtles with FP with particular near-
shore localities (such as the Indian River Lagoon) suggests that
turtles become infected with CFPHV after they migrate as
juveniles to these localities (10). The epizootic transmission
cycle is perpetuated in areas with high FP prevalences, as
tumors are a known source of transmissible virus (21, 24). The
high prevalence of CFPHV gH antibodies in the Trident Basin
population suggests, however, that there may be alternate virus
transmission cycles involving virus replication and shedding
from tissues other than cutaneous tumors. How CFPHV or
antigenically similar chelonid herpesviruses are transmitted in
apparently healthy FP-free populations is a major question.
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